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AIphal-antitrypsin genetic polymorphism in ANCA-positive systemic
vascufitis. AIphal-antitrypsin (al-AT) is the major inhibitor of protein-
ase 3 (PR3), the main target antigen of antineutrophil cytoplasm
antibodies (ANCA) in Wegener's granulomatosis. al-AT is encoded by
a polymorphic gene, with over 75 alleles, defining severely, medium and
non-deficient protease inhibitor (P1) phenotypes. We describe the
association of severely and medium deficient P1 phenotypes with
anti-PR3 positive systemic vasculitis, and postulate a pathogenetic role
for al-AT deficiency and the occurrence of ANCA, with specificity for
PR3 in a subgroup of patients with Wegener's granulomatosis.
Antineutrophil cytoplasm antibodies (ANCA) are found in
the sera of patients with systemic necrotizing vasculitis [1, 2].
These autoantibodies have been implicated in pathogenesis
since their titer correlates with disease activity [2—4], and rises
before clinical relapse [5]. ANCA have been shown to induce
neutrophil activation in vitro, thereby releasing protease and
toxic oxygen radical species [6], which may be responsible for
the histological abnormalities found in these diseases. The main
antigenic targets for ANCA are proteinase 3 (PR3) [7—9] and
myeloperoxidase [10].
AIphal-antitrypsin (al-AT), a key protein involved in immu-
nological regulation [11], is the major inhibitor of PR3 [12, 13],
a polymorphonuclear leukocyte proteinase first described as an
emphysema-producing agent in hamsters [14]. The body de-
pends even more heavily on al-AT for control of PR3 activity
than it does for elastase activity, which is controlled by addi-
tional inhibitors [131. al-AT is encoded by a highly polymorphic
gene, with at least 75 alleles known to date at the so-called P1
(protease inhibitor) locus [15, 16]. With respect to circulating
al-AT levels, P1 alleles may be classified as either "normal",
"deficient" (low serum level), "dysfunctional" (normal level of
a non-functioning al-AT), or "null" (no al-AT detectable).
The two parental genes are codominantly expressed, and vari-
ous degrees of al-AT deficiency may be observed according to
deficient allele combinations [15—17]. Based on electrophoretic
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patterns of al-AT in serum, the protease inhibitor (P1) pheno-
type of a patient can be defined. Severe al-AT deficiency is a
risk factor for the development of panlobular emphysema
[18—20], various hepatic disorders in childhood and adults [18,
20], and auto-immune disorders including anterior uveitis [21],
systemic lupus erythematosus [22], and neutrophilic ulcerative
panniculitis [23, 24]. In adults with al-AT deficiency, isolated
case reports have indicated the possible occurrence of cutane-
ous [25, 26] or systemic vasculitis [25, 27—29], Goodpasture's
syndrome [25], and necrotizing glomerulonephritis [25, 28, 29].
In this study we determined al-AT phenotypes in 14 consec-
utive ANCA-positive patients with systemic vasculitis.
Methods
Patients
Fourteen consecutive patients followed in our institution
were selected for this study. Their main clinical features are
summarized in Table 1. There were eight males and six females
with the mean age being 53.6(25 to 76 years). Clinical diagnoses
were Wegener's granulomatosis in four, clinically suspected
Wegener's disease without granuloma in eight, and microscopic
polyarteritis in two cases.
ANCA assays
ANCA ELISA. Sera were assayed for ANCA activity by an
ELISA derived from a radioimmunoassay using a neutrophil
extract prepared as previously described [2].
Antigen specic assays. IgG anti-MPO assays were per-
formed as described elsewhere [30]. IgG anti-PR3 antibodies
were detected using a commercially available ELISA kit (Bio-
Carb, Sweden) according to the manufacturer's instructions.
Indirect immunofluorescence (hF). Positivity for ANCA on
the ELISA was confirmed by hF as described [31].
Aiphal-antitrypsin (al-AT) assays
P1 phenotypes were determined by isoelectric focusing as
described [32].
Statistical analysis
P1 phenotypes were classified as either severely deficient (P1
Z phenotype, either homozygous for the deficient Z allele or
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Table 1. Clinical and biological features
Patients Age Sex Diagnosis
Organ
involvement
ANCA
specificity
P1
phenotype
1 30 F W KEMN PR3 ZZ
2 38 F WG KLEJNS PR3 ZZ
3 51 M W KLEyJ PR3 ZZ
4 68 M MPA KLJNS PR3 M1Z
5 25 F W KES PR3 M1Z
6 33 M W KEJ PR3 IS
7 57 M W KEJS PR3 M1
8 60 F WG LEJ PR3 M2
9 74 M WG ELEy MPO M1Z
10 63 M MPA K MPO M1S
11 68 F W KEJS MPO M2S
12 72 M W ENEy MPO M1M2
13 36 M WG KLEM MPO M
14 76 F W KEJ MPO M2
Abbreviations are: sex, F (female), M (male); diagnosis, WG (We-
gener's granulomatosis), W (clinically suspected Wegener's disease),
MPA (microscopic polyarteritis); organ involvement, K (kidney), L
(lung), E (ENT), Ey (eye), J (arthritis), S (skin), M (muscle), N (nervous
system); ANCA specificity: PR3 (proteinase 3), MPO (myeloperoxi-
dase),
Z-null), medium deficient (heterozygous deficient P1 MZ or
homozygous moderately-deficient P1 S and P1 SZ) or non-
deficient (mainly P1 M1, P1 M2, P1 M1M2, P1 IS, P1 IM, P1 FM,
and P1 MS).
The distribution of severely deficient, medium deficient and
normal P1 phenotypes was compared (G test and Fisher exact
probability) between the anti-PR3 or anti-MPO positive popu-
lations and a historical control group of 1,310 normal individu-
als previously studied in the same referring area by the same
laboratory [32, 33].
Results
ANCA assays
All patients were ANCA positive both in IgG ELISA and hF
studies. Antigen specificity was PR3 in eight and MPO in six
(Table 1).
Aiphal-antitrypsin assays
Three patients had severe al-AT deficiency (PT ZZ). ANCA
in these patients recognized PR3 in all cases and not MPO
(Table 1). Diagnoses were Wegener's granulomatosis or clini-
cally suspected Wegener's disease. All three had rapidly pro-
gressive glomerulonephritis, and two had severe lung vasculitis,
one of whom also had panlobular emphysema and died of
respiratory failure. Other pathological manifestations included
ear-nose-throat (ENT) and ocular vasculitis, arthralgia, myal-
gia, neuropathy and skin rash (Table 1).
Three other patients had heterozygous deficient P1 pheno-
types (P1 MZ), two with anti-PR3 and one with anti-MPO
antibodies (Table 1).
Eight patients had no al-AT deficiency (PT M, P1 MS or P1
IS), including three patients with anti-PR3 and five with anti-
MPO antibodies (Table 1).
Table 2. P1 phenotypes in anti-PR3 and anti-MPO positive patients
and controls
P1 phenotype PR3 MPO Controls
Severely deficient
(Z)
Medium deficient
(MZ, SZ, S)
Non-deficient (M,
MS, IM, IS, FM)
3 (37.5%)
2 (25%)
3 (37.5%)
0 (0%)
1 (16.7%)
5 (83.3%)
0 (0%)
55 (4.2%)
1,255 (95.8%)
Results are given as the absolute number of patients (% in each
Statistical analysis
The prevalence of severely deficient, medium deficient and
normal PT phenotypes in the anti-PR3 and anti-MPO positive
groups was compared to a control population from the same
region. The distribution of P1 phenotypes was significantly
different in the anti-PR3 (0 = 6.543, df = 2, P < 0.05) but not
in the anti-MPO positive population (G = 1.108, df = 2, P =
0.607; Table 2). This was related to the highly significant
increase of P1 Z homozygotes in the anti-PR3 positive popula-
tion (Fisher's exact probability 9 x 10—v).
Discussion
We describe the association of alphal-antitrypsin (al-AT)
deficiency with anti-proteinase 3 (PR3) positive, but not anti-
MPO positive systemic vasculitis. al-AT deficiency was previ-
ously reported in isolated cases of cutaneous or systemic
vasculitis [25—29], but the prevalence of the defect may have
been under-estimated since patients were not routinely tested
for the P1 phenotype.
This study suggests a possible involvement of the protease/
protease inhibitor imbalance in the pathogenesis of at least part
of the anti-PR3 positive systemic vasculitides. PR3, a neutral
serine proteinase present in the primary granules of neutrophils,
is the main target antigen of ANCA in Wegener's granuloma-
tosis [7—9], al-AT is the major inhibitor of PR3 [12, 13] and
elastase [34], and the balance between protease and anti-
protease activity is crucial in maintaining homeostasis. In
normal circumstances, proteases released by degranulation
after neutrophil activation are rapidly inhibited by a large
excess of al-AT [35]. In homozygous and heterozygous al-AT
deficiency, increased human leukocyte elastase (HLE) activity
is observed [36], indicating an imbalance between protease and
protease inhibitor. HLE in excess can hydrolyse the Met-358-
Ser-359 bond of al-AT and degrade al-AT into two fragments
without protease inhibitor capacity, worsening the protease/
protease inhibitor imbalance. The two al-AT degradation prod-
ucts have respective molecular masses of 47,800 and 4,200 kD,
the latter being a potent chemotactic factor [37] amplifying
inflammatory response. In the context of this protease/protease
inhibitor imbalance, al-AT deficiency may lead to increased
levels of PR3, which would be more accessible to the immune
system. Infection, which appears to play a key role in initiating
systemic vasculitis relapses [38], may therefore act both
through an inflammatory cytokine release, amplifying neutro-
phil activation, and a worsening of the protease/protease inhib-
itor imbalance.
Our data do not indicate that al-AT deficiency is the only
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predisposing genetic defect leading to anti-PR3 positive sys-
temic vasculitis, since some of our anti-PR3 positive patients
had normal P1 phenotypes, and one center study did not find
such a high prevalence of deficient P1 phenotypes in another
group of patients [39]. Whatever the frequency of al-AT
deficiency in anti-PR3 positive vasculitis, this study points out
a possible role for protease/protease inhibitor imbalance in the
pathogenesis of the disease and ANCA production. Further
studies are needed in populations of various genetic back-
grounds to evaluate the correlation between al-AT or other
protease inhibitor deficiencies and ANCA autoimmunity, since
risk factors probably include HLA class II specificities [40].
Our observations do not rule out the possible pathogenetic
role of ANCA in systemic vasculitis. ANCA might be one of
several co-factors needed for the occurrence of neutrophil
activation and vasculitis. Most al-AT deficient patients will
never develop vasculitis, which is closely associated with the
presence of ANCA. In normal individuals, the interaction
between al-AT and a protease is irreversible and leads to
removal of the complex from circulation [37]. In al-AT defi-
cient patients, the availability of free PR3 may lead to compe-
tition between ANCA and al-AT binding, resulting in only
partial enzymatic inhibition. Van de Wiel et al recently showed
that C-ANCA but not P-ANCA could inhibit the formation of
PR3/al-AT complexes [41]. However, C-ANCA also partly
inhibited the proteolytic activity of PR3 with different rates,
depending on the substrates involved as well as on interpatient
differences [41]. Therefore, the significance of the tripartite
interaction of PR3, al-AT and ANCA in vivo remains unclear.
Comparable data have been obtained with MPO and anti-MPO
antibodies [42].
Although emphysema is likely to appear in severe al-AT
deficient patients [19], the number of adults presenting emphy-
sema between the ages of 45 and 55 is less than 10% of the
expected number of P1 Z homozygotes in this age band [20].
Although a certain number might have died from liver disease,
and others might present subclinical emphysema, it is possible
that a large proportion of al-AT deficient subjects, particularly
nonsmokers [15], will not suffer from pulmonary disease, or
only in the elderly [43]. Indeed, two of our three P1 Z homozy-
gous patients did not exhibit severe alteration of lung function,
and only one had panlobular emphysema, developed a severe
lung vasculitis and died from respiratory failure.
We have described an association between al-AT deficiency
and anti-PR3 positive vasculitis. Determination of the exact risk
factor associated with this genetic defect will require further
studies in conjunction with analysis of other markers, including
other protease inhibitor deficiencies and HLA class II specific-
ities.
Reprint requests to Pr. V.L.M. Esnauk, Laboratoire d'Immuno!ogie,
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